Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 5,199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Active, not recruiting Phase 1 Interventional

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

NCT05353439
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Tazemetostat Hydrobromide, Topotecan Hydrochloride
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Newport Beach, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00555256
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
sunitinib and rapamycin (Drug will be held)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 28, 2026, 1:38 AM EDT
Recruiting Phase 4 Interventional

EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

NCT06105801
View directory record Official record
Conditions
Lung Cancer
Interventions
Endobronchial ultrasound with transbronchial needle aspiration, Bronchoscopy, Cryobiopsy
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 1:38 AM EDT
Recruiting No phase listed Observational

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT06904365
View directory record Official record
Conditions
Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions
HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 3 Interventional

Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer

NCT00003831
View directory record Official record
Conditions
Lung Cancer
Interventions
conventional surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
70
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

NCT03509012
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
Interventions
Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Tucson, Arizona • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 28, 2026, 1:38 AM EDT
Recruiting No phase listed Observational

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT01950572
View directory record Official record
Conditions
Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Oltipraz in the Prevention of Lung Cancer in People Who Smoke

NCT00006457
View directory record Official record
Conditions
Lung Cancer
Interventions
oltipraz
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 28, 2026, 1:38 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

NCT06898957
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
YL201, Tarlatamab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Irvine, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

NCT00596830
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Not applicable Interventional

Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00559611
View directory record Official record
Conditions
Lung Cancer
Interventions
Endobronchial Ultrasound, Mediastinoscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 2 Interventional Results available

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

NCT02872701
View directory record Official record
Conditions
Lung Neoplasms, Lung Cancer
Interventions
OTL38 for Injection, Near infrared camera imaging system, Endoscopic or Thoracic Surgery
Drug · Device · Procedure
Lead sponsor
On Target Laboratories, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 28, 2026, 1:38 AM EDT
Completed No phase listed Observational

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

NCT02245100
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
Cytology specimen, Laboratory biomarker analysis
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 2 Interventional

Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00072527
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, etoposide, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
76
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 28, 2026, 1:38 AM EDT
Active, not recruiting Phase 1 Interventional

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

NCT03923270
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Olaparib Pill, Thoracic Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

NCT00093756
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
143
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 28, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

NCT00203931
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab, Pemetrexed
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 28, 2026, 1:38 AM EDT
Recruiting Phase 2 Interventional

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

NCT07603856
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

NCT03353675
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
TG4010, Chemotherapy, Nivolumab
Biological · Drug
Lead sponsor
Transgene
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

NCT00324805
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Bevacizumab, Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium, Questionnaire Administration, Vinorelbine Tartrate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1139
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 712 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed Not applicable Interventional

Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

NCT05342675
View directory record Official record
Conditions
Lung Cancer, Pneumothorax
Interventions
Rapid Rollover
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 1:38 AM EDT
Not yet recruiting Not applicable Interventional

Evaluation of Endobronchial Ultrasound Needle Cleaning Techniques and Their Impact on Specimen Contamination

NCT07461662
View directory record Official record
Conditions
Lung Cancer (Locally Advanced or Metastatic)
Interventions
Purge cleaning
Diagnostic Test
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 28, 2026, 1:38 AM EDT
Completed No phase listed Observational Results available

Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors

NCT02233842
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Bladder Cancer, Thymic Cancer
Interventions
Participant interview
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years to 110 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 28, 2026, 1:38 AM EDT